New study investigates Wegovy's safety in pregnancy

NCT ID NCT05503927

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at health records of about 1,100 women who took Wegovy during pregnancy and compares them to those who did not. The goal is to see if the drug increases risks for birth defects or other problems in babies. Researchers will use insurance claims data to track outcomes like major birth defects and low birth weight.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • IBM Watson Health™ Truven Marketscan

    Ann Arbor, Michigan, 48108, United States

  • Novo Nordisk Investigational Site

    Princeton, New Jersey, 08540, United States